How to Use Genetic Testing in Your Office
Expert faculty discuss when to consider genetic testing, how to use advanced techniques, the process of ordering tests, interpreting results, and strategies for managing complex genetic findings, including challenging variants.
Price: FREE for members and non-members
Recorded on: November 13, 2024
Time to complete: 1 hour
CME is not offered for this activity.
Supported by Pharming.
Additional Resources
Genetic Testing Resources
Clinical Webinar Archive
Target Audience
Allergists and allied health professionals working with allergists.
Learning Objectives
After this webinar, participants should be better able to:
- Describe the fundamental principles of genetic testing, including its purpose and application in clinical practice.
- Apply knowledge of genetic testing to determine the appropriate use of various genetic tests in patient care.
- Evaluate the effectiveness of different genetic tests in diagnosing and managing patient conditions.
- Assess and interpret genetic testing results to inform clinical decision-making and patient management strategies.
Disclosure Statement
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.
Moderator:
Todd A. Mahr, MD, FACAAI, is the Executive Medical Director at the ACAAI. Dr. Mahr is a pediatric allergist at Gundersen Health System. He has been practicing for over 35 years.
Disclosures:
Aimmune Therapeutics, Inc. – Advisor; AstraZeneca – Speaker; GlaxoSmithKline – Speaker; Regeneron – Advisor, Speaker; Sanofi – Advisor, Consultant
Faculty/Panelists:
Nicholas L. Hartog, MD, FACAAI, is a clinical associate professor at Michigan State University College of Human Medicine. Dr. Hartog is also head of adult and pediatric immunodeficiency clinic at Corewell Health and Helen Devos Children's Hospital. His clinical interests focus on primary immunodeficiency. He has many active research projects in the field of immunodeficiency and RNA sequencing.
Disclosures:
X4 – Speaker; ADMA Biologics – Speaker; Amgen – Advisor, Consultant, Speaker; Chiesi – Consultant; Pharming – Advisor, Consultant, Speaker; Takeda – Speaker
Daniel L. Rosenberg, MD, is an Assistant Professor of Allergy & Immunology at the University of Wisconsin Hospital and Clinics. In his role as an Assistant Professor of Medicine, he is an Allergist and Immunologist at the University of Wisconsin School of Medicine and Public Health within the Department of Medicine. He has an Adult Immunology clinic that specializes in genetic testing for rare inborn errors of immunity. His research interests include medical education, curriculum development, and quality improvement in the management of drug allergy.
Disclosure:
Nothing to disclose
Eric M. Schauberger, DO, PhD, FACAAI, is a Pediatric Allergist at Gundersen Health in La Crosse, WI. He is an Adjunct Professor of Pediatrics at the University of Wisconsin. Eric has a PhD in Genetics and a research interest in early life risk factors of asthma and allergies. He also has a clinical interest in drug allergy delabeling.
Disclosure:
Nothing to disclose
CME is not offered for this activity.
Note
Hardware Requirements:
Processor: 1 GHz (min), 2GHz dual core or more recommended
RAM: 4 GB, 8 GB recommended for optimal performance.
Software Requirements:
Browsers: Latest versions of Google Chrome (recommended for best compatibility), Mozilla Firefox, or Microsoft Edge.
Browser Settings:
-Enable Cookies
-Enable Pop-ups (in both Internet browser and security software)
-Enable Javascript
Media Viewing: PDF Reader, Adobe Flash, Microsoft Office.
Operating System: Windows 10 or later (Windows 11 recommended), macOS 10.15 (Catalina) or later (macOS 13 Ventura recommended for best compatibility), iPadOS 16 or later.
Internet: Broadband connection (5Mbit/sec or faster)